



- Meeting opens
- Chairman's address
- **Ordinary business**
- Meeting closes



#### Chairman's address

SLEEP DIAGNOSTICS EXCELLENCE Since 1987



#### Resilience and growth

- Compumedics commercial and financial resilience, despite extremely tough post GFC international markets for medical capital equipment, particularly in the US, sees it well placed for the forecast period
- Compumedics' product innovation remains on track delivering significant new products this year, including:
  - Neuvo® EEG long-term monitoring (LTM) device a new product in a new market for Compumedics
  - Grael® PSG / EEG a new generation in sleep diagnostics systems - a new product in an existing market for Compumedics
- All medical innovation (step-out growth) opportunities have advanced closer to commercialisation during the year





# Compumedics is a world leading supplier of medical technology for patient monitoring.

Compumedics' primary healthcare markets cover sleep, brain and ultrasonic blood flow monitoring.

- Our Vision is to set the innovative and technological standards for patient monitoring technologies in our chosen markets.
- •We aim to deliver superior returns to our shareholders by identifying and delivering innovative and accessible medical technologies globally in our chosen markets.
- •We provide our customers with products and software solutions of superior technology, ease of use and reliability.

SLEEP DIAGNOSTICS EXCELLENCE Since 1987





#### Global reach

- Corporate headquarters in MELBOURNE, Australia
- Sales, marketing and support offices in
  - Melbourne, Australia
  - Charlotte, North Carolina, USA
  - Singen, Germany
  - Hamburg, Germany





· Network of Distributors Globally





# Strategic growth drivers

- The expansion of our core sleep and neurological diagnostic monitoring businesses in Europe, specifically, Germany and France, with Germany well underway and France in the formative stages.
- The entry of Compumedics into the global LTM EEG market with the world-wide release of its new innovative LTM device, Neuvo®. The Company has secured initial sales of the device in Europe and Australia and has several opportunities in the US it is currently pursuing.
- The evolution of the home-sleep testing (HST) market in the US as a result of changes to US private and government funding of HST and the expected growth in sales of small, limited channel sleep-diagnostic screener devices.






### Financials - summary

	2007 actual	2008 actual	2009 actual	2010 actual
Revenues (\$m)	36.7	38.5	38.4	32.4
Margins %	58%	58%	57%	59%
Other income	0.1	0.4	0.6	0.2
Operating Expenses	19.5	20.3	19.6	18.9
EBITDA	1.3	1.9	3.7	1.2
NPAT	0.1	0.8	2.7	0.4
AUD/USD exchange rate	0.78	.90	0.75	0.88

EXCELLENCE
Since 1987





- Total revenues were \$32.4m compared to \$38.2m in the prior year. On a constant currency basis prior year revenues were \$33.4m
- FY2010 NPAT of \$0.4m compared to the prior year result of \$2.7m
- Bank debt reduced year-on-year by a further 14% from \$2.2m to \$1.9m, cash at \$1.8m compared to \$2.6m last year
- Many new products released including, Grael®, Neuvo®, Xegis®
- SomniLink® SPAP® shipping to Italy





#### Financials – key points

- Gross margins stronger at approximately 59%
- Operating expenses less investing activities stable with last year's spending - \$18.9m compared to \$19.7m in the prior year
- EBITDA at \$1.2m compared to prior year profit of \$3.4m
- Operating cash was \$0.5m for the year ended 30 June 2009, compared to the prior year result of \$3.7m


SLEEP DIAGNOSTICS EXCELLENCE Since 1987





### Financials – key points


- Borrowing costs at \$0.6m were in line with the prior year
- Sales in Europe were down 4% as reported, however in constant currency growth of 13% was achieved. Sales in the US were down 26% as reported, or 12% in constant currency. In Asia Pacific (including Australia) sales were down 14% as reported, or 8% in constant currency. This reflects the ongoing effects of the GFC in key markets for our products.
- Net foreign exchange was a \$1.2m charge for FY2010 being an adverse \$2.0m turnaround than the \$0.8m gain FY2009

SLEEP DIAGNOSTICS EXCELLENCE Since 1987











#### ..so, how has it turned out so far?

- · Private company (1999) turnover \$9m pa with 45 staff (1 US based)
- Listed on ASX (December 2000) raised \$11m (post fees/debt)
- April 2002 purchased US based Neuroscan world's leading source localisation software – Compumedics turnover \$34m, with 120 staff (50 US based and 4 Germany-based)
- September 2004 purchased German based DWL ultrasonic blood flow business – one of the global founders of this technology – Compumedics turnover now \$38m, generating profits, with 160 staff (55 US based, 30 Germany-based)
- June 2005 having amassed a world-class intellectual property portfolio around sleep, brain and ultrasonic blood-flow monitoring Compumedics losses close to \$5m – grown too quickly, stretched the financial, management and human resource capability of the Company too far


SLEEP DIAGNOSTICS EXCELLENCE Since 1987



#### ..so how has it turned out so far

- June 2006 Compumedics reduced loss for the year to \$1.6m and maintains sales and product development of IP portfolio
- June 2008 Compumedics 2 years into its performance transition program - returned to profits (\$0.8m), has grown revenues to \$38m despite a rising exchange rate and has 160 staff (60 US based and 40 European based)
- June 2009 Compumedics sets record profit of \$2.7m on revenues of about \$38m despite GFC.
- Offices established in key markets in USA (Charlotte, NC), Germany (Hamburg and Singen) and the home office in Australia (Melbourne)
- Compumedics is poised, with the existing management team, to resume historical growth from key growth opportunities including new product releases Grael® PSG/EEG, Neuvo® LTM EEG and Somnilink® SPAP® and HST market in the USA


SLEEP DIAGNOSTICS EXCELLENCE Since 1987































### Core products: Brain research



#### Source


Offers impressive source localisation capabilities, including several dipole models and three spheres, BEM and FEM reconstructions.





#### Stim

Presents audio and video stimuli and sends stimuli and response to Scan where they are incorporated into the data file.











#### **Summary**

- · World-class patient monitoring Company
- Uniquely placed in key global markets with strong growth opportunities
- Strong financial position despite continued tough post-GFC market conditions, particularly in the US
- Established routes to market in key international markets combined with increased sales resources and new products should allow our proven formula for long term growth and value creation to continue
- Substantial core and new breakout (sleep treatment) growth opportunities to drive the business forward





## **Ordinary Business**

- Item 1 Financial Statements and Reports (non binding resolution)
- · Item 2 Election of a Director
- Item 3 Adoption of Remuneration Report (non binding resolution)

'Defining Life's Signals'



